HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo for HER2 cancers shows early promise but trial ends early
Disease control TerminatedThis study tested a new drug called BDC-1001, alone or with another drug (nivolumab), in people with advanced HER2-positive cancers (like breast, stomach, or colon cancer) that no longer responded to standard treatments. The goal was to check safety and see if tumors shrank. The …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising combo for brain metastases falls short in early trial
Disease control TerminatedThis study tested a combination of two drugs (ASLAN001 and capecitabine) in people with HER2-positive breast cancer that had spread to the brain and was growing despite prior radiation. Only 3 participants were enrolled before the study was stopped early. The goal was to see if t…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Heart-Saving combo tested for breast cancer patients
Disease control TerminatedThis pilot study aimed to see if giving heart medications (carvedilol and empagliflozin) before or during HER2-targeted breast cancer treatment could prevent heart damage. Only 7 of the planned 20-40 participants were enrolled before the study was stopped early. The goal was to t…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Hard-to-Treat breast cancer? study cut short
Disease control TerminatedThis study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with several therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink tu…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Breast cancer surgery omission studied in Low-Risk patients
Disease control TerminatedThis study looked at whether women with a specific type of early-stage breast cancer (HER2-positive, low-risk) could safely avoid surgery if their tumors completely disappeared after standard drug therapy. Only 5 participants were enrolled before the study was stopped early. The …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fundacio Clinic Barcelona • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Promising brain metastasis combo trial halted after just one patient
Disease control TerminatedThis study aimed to see if combining three drugs (tucatinib, trastuzumab, capecitabine) with precise radiation (SRS) could safely control brain tumors from HER2+ breast cancer. Only one person enrolled before the trial was stopped early. The main goal was to find safe doses and w…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
MRI scans may predict immune response in HER2+ breast cancer
Knowledge-focused TerminatedThis study looked at whether special MRI scans can detect early signs of immune response in women with HER2-positive breast cancer after one round of anti-HER2 treatment. Researchers enrolled 13 adults with stage I to III breast cancer who were scheduled for surgery and anti-HER2…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 03:15 UTC